Adaptive Biotechnologies Corp. (ADPT)
24.02
-1.56
(-6.10%)
USD |
NASDAQ |
Oct 16, 16:00
24.03
+0.01
(+0.04%)
After-Hours: 20:00
Adaptive Biotechnologies Research and Development Expense (Annual) : 83.81M for Dec. 31, 2025
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2025 | 83.81M |
| December 31, 2024 | 94.33M |
| December 31, 2023 | 101.58M |
| December 31, 2022 | 121.84M |
| December 31, 2021 | 130.09M |
| Date | Value |
|---|---|
| December 31, 2020 | 109.30M |
| December 31, 2019 | 65.64M |
| December 31, 2018 | 37.04M |
| December 31, 2017 | 29.90M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Annual) Benchmarks
| Champions Oncology, Inc. | 9.084M |
| Medpace Holdings, Inc. | -- |
| Avantor, Inc. | -- |
| Personalis, Inc. | 50.26M |
| 10X Genomics, Inc. | 238.63M |